INTRODUCTION
As more and more patients are developing renal failure and the dialysis population in most countries continues to rise, nephrologists are devoting increased efforts to prevent this world-wide epidemic of end-stage renal disease. Essential to this effort is a better understanding of how renal disease progresses to fibrosis even after the initial insult is no longer operative.
In the past few years many investigators have studied the phenomenon by which various renal cells transform themselves into so-called myofibroblasts. Challenging the previously accepted theory that fibrosis is the result of migration of fibroblasts from outside into the kidney, the new concept envisions transformation of residing kidney epithelial cells into myofibroblasts (epithelial-mesenchymal transformation, EMT) as the main event leading to fibrosis.
In vitro evidence for EMT
Until recently it was believed that organ fibrosis occurred by migration of fibroblasts from outside into the organ. In 1995 Strutz et al challenged this widely accepted hypothesis (1) . In their search for a marker for fibroblasts, they found a protein specific for fibroblasts, subsequently naming it fibroblast specific protein-1 (FSP-1). Although FSP-1 positive fibroblasts were sparse in the normal kidney, when a mouse kidney with interstitial fibrosis was stained for FSP-1, tubular epithelial cells in areas of fibrogenesis had now begun expressing FSP-1. From this observation, it was concluded that a new mechanism may play a role in organ fibrosis, namely the conversion of kidney epithelial cells into fibroblasts (1) .
The signal most consistently associated with EMT is transforming growth factor-ß (TGF-ß). This was first discovered by Roberts et al in 1981, when they described a new class of transforming growth factors (potentiated by epidermal growth factor) causing anchorage independent growth of non-neoplastic indicator cells (2) . TGF-ß is a 25 kilodalton homodimeric polypeptide (3) . Even though most cell types secrete TGF-ß, certain cells are thought to be its main source in tissue fibrosis (4) . Activation of peripheral blood leukocytes and lymphocytes has been shown to cause them to secrete TGF-ß and even lead tubular cells to undergo EMT (5, 6) . Not surprisingly platelets also contain large amounts of TGF-ß, which is intimately involved in wound repair (7) . Nearly all cells (and specifically kidney, mesangial, endothelial, and epithelial cells) possess TGF-ß receptors (3) (4) 8) .
In vitro evidence that kidney epithelial cells can convert into myofibroblasts came in 1999, when Fan et al treated a rat tubular epithelial cells line (NRK52E) with TGF-ß and observed EMT (9) . Between doses of 1-50 ng/mL, the TGF-ß effect was dose-dependent. However, in 2001, Yang et al showed induction of α-smooth muscle actin (α-SMA, marker of myofibroblasts) in human tubular epithelial cells (HKC) at TGF-ß concentrations as low as 0.1 ng/mL, with the effect reaching a plateau at a concentration of 2 ng/mL (10) . In 2002, Tian et al treated human tubular epithelial cells (HK-2) with TGF-ß (at a concentration of 10 ng/mL) and observed EMT after two days of incubation (11) . Occurrence of EMT was observed whether TGF-ß was applied to the apical or basolateral side of the cells. In similar experiments, other investigators also observed EMT of proximal tubular epithelial cells into myofibroblasts (11, 12) . Treatment of HK-2 cells with activated peripheral blood monocytes (PBMC) conditioned medium also leads to EMT of these cells (13) .
In vitro data that kidney cells other than tubular cells undergo EMT is not as strong. In 1993, when Yoshioka et al stained the glomeruli of kidneys with TGF-ß antibody, they observed linear staining along the glomerular basement membrane and weak staining in the mesangium (14) . In preliminary experiments, glomerular visceral epithelial cells have undergone EMT when treated with TGF-ß under similar conditions as tubular epithelial cells (15) . In accordance with these findings, it has been thought that podocyte injury plays a central role in glomerulosclerosis (16) .
In vivo evidence for EMT
Evidence for in vivo EMT includes increased TGF-ß levels in diseased states, correlation of TGF-ß levels with fibrosis, induction of fibrosis by TGF-ß, and demonstration of EMT in animal/human kidneys. As early as 1990, high TGF-ß levels were seen in mesangial proliferative glomerulonephritis in mice (17) . In humans it was not until 1993 that an increase in the expression of TGF-ß mRNA and protein was seen in the glomeruli of human diabetic kidneys (7) . In 1995, elevated glomerular expression of TGF-ß mRNA and protein was reported in patients with mesangial proliferative glomerulonephritis, including IgA nephropathy (18) . Fur thermore there was positive correlation between TGF-ß levels and the degree of glomerulosclerosis. Subsequently overproduction of TGF-ß was also confirmed in focal segmental glomerulosclerosis, crescenteric glomerulonephritis, lupus nephritis, and HIV associated nephropathy (19, 20) . TGF-ß levels were associated with accumulation of extracellular matrix (20) . Again in 2000 and 2002, when diabetic nephropathy was studied in both experimental and human systems, elevated TGF-ß levels were documented in the glomeruli (3, 21) . Finally increased TGF-ß levels have been seen in unilateral ureteral obstruction model in the rat (10) . Not only are TGF-ß levels elevated in kidney disease, but TGF-ß receptors are also upregulated in areas of renal damage (22) .
In order to gain more insight onto the mechanisms of EMT, one can also stain the diseased kidney with tubular markers (i.e. E-Cadherin) or markers of myofibroblasts (α-SMA). When the diseased kidney was stained for α-SMA, strong staining was seen in the interstitium, with minimal staining in the glomeruli (23) . At the same time when the kidneys were stained for TGF-ß, staining was seen in the cytoplasm of tubular epithelial cells, in the renal interstitium, and in the glomeruli of patients with glomerulonephritis. In a model of crescenteric glomerulonephritis in the rat, α-SMA staining was seen in both glomerular visceral and parietal epithelial cells at week 3 (24) . Most cells within the cellular and fibrocellular crescents expressed TGF-ß and basic fibroblast growth factor (FGF).
Even though crescents traditionally are believed to be made up mostly of parietal epithelial cells, Moeller et al, using podocyte specific 2.5 P-Cre mouse line, showed that podocytes make up at least one quarter of the cells in the glomerular crescents (25) . When TGF-ß levels were studied in IgA nephropathy, it was thought that resident mesangial and endothelial cells were the main source of TGF-ß (18) .
If exogenous TGF-ß administration leads to kidney disease and blocking TGF-ß action inhibits fibrogenesis, then the role of TGF-ß in organ fibrosis will be best solidified. In preliminary experiments intrarenal infusion of TGF-ß gene caused glomerulosclerosis in rats (21) . More extensive data for TGF-ß infusion causing EMT in vivo is lacking at this time. Also other factors other than TGF-ß may still play a role in EMT, and also EMT as the main mechanism for TGF-ß induced fibrosis would still have to be proven.
Although the above in vivo data, combined with the findings in vitro, suggest the existence of EMT, more direct proof is needed. In 2001, Jinde et al stained human kidneys with various kidney diseases for α-SMA, collagen and cytokeratin (26) . It was shown that tubular cells lost cytokeratin and had de novo collagen staining. Most interestingly there were tubular cells in the intermediate stage where the cuboidal epithelial cell expressed both cytokeratin and α-SMA. Since these cells possessed both epithelial and mesenchymal characteristics, the authors concluded the existence of EMT. Similarly in a rat model of 5/6th nephrectomy, Ng et al. observed EMT in tubular epithelial cells (27) . More specifically on electron microscopy looking at the actin filaments, progressive loss of epithelial characteristics and gain of mesenchymal characteristics were seen. More directly in 2002, using bone marrow chimeras and transgenic reported mice, it was shown that interstitial kidney fibroblasts derive from two sources (28) . A small number migrate to interstitial spaces from the bone marrow but more importantly, FSP-1+ fibroblasts arise in large numbers by local EMT during renal fibrogenesis. It was also shown that TGF-ß and EGF induce the expression of FSP-1 in transitioning tubular epithelium.
Looking at a different aspect of endstage renal disease, it is well known that peritoneal mesothelial cells undergo changes with prolonged dialysis treatment. The fibrosis of these cells results in inadequate fluid and toxin removal by peritoneal dialysis. Recently it has been shown that peritoneal mesothelial cells undergo EMT after prolonged peritoneal dialysis (29) .
The steps of EMT
In order for an epithelial cell to convert into a fibroblast several events must happen. The epithelial cell has to lose its epithelial characteristics, then it has to acquire mesenchymal characteristics, and finally it must breakdown basement membrane, have increased motility, and produce extracellular matrix. Loss of E-cadherin (an epithelial cell marker) occurs at six hours after incubation of tubular epithelial cells (HKC) with TGF-ß and is the first main event during EMT (10) . The second event is gain of mesenchymal markers (α-SMA), which occurs at 36 hours in proximal tubular cells and at eight hours in interstitial fibroblasts (10, 30) . Then there is marked increase in matrix metalloproteinase-2 (MMP-2) secretion at 48 hours (10). Separate experiments have also shown elevated gelatinase A and B levels by glomerular epithelial cells upon TGF-ß treatment (31) . The thought is that the newly formed fibroblasts need to breakdown the basement membrane and move from the tubular area to the interstitium; accomplishing this goal requires gelatinases. Increased motility of the transformed cells is also observed at two days (10) . In summary, EMT is associated with cell scattering, loss of intercellular junctions, and acquisition of cell motility (32) . The last step in fibrogenesis is increased extracellular matrix production, which has been demonstrated in many cell types both with TGF-ß activation and also during EMT (6, 8, 33) .
Factors that promote or inhibit EMT
Although TGF-ß is the strongest stimulus for EMT, at least in vitro, other factors may produce EMT under the right circumstances. Furthermore there are many factors that potentiate TGF-ß action or lead to more TGF-ß production. Not only is diabetes associated with kidney disease, but also at times it leads other organs to function inappropriately. As high glucose is the hallmark of diabetes, several investigators have tried to correlate high glucose levels with TGF-ß production. Abbate et al in 2002, found TGF-ß overproduction by cultured glomerular epithelial cells in response to high glucose (16) . In another study, Valtez observed that treating mesothelial cells in vitro with a high glucose concentration induced expression of TGF-ß and reduces E-cadherin levels (29) . Another prominent feature of type 2 diabetes, at least in the early stages, is hyperinsulinemia. When human tubular cells (HK-2) were incubated with insulin, again high levels of TGF-ß was seen (34) . Recently the toxicity of severe proteinuria to the kidney tubulointerstitium has received attention. When effects of excess intraglomerular passage of proteins on podocytes was studied, elevated TGF-ß levels were found (16) . Lastly thrombospondin has been shown to activate TGF-ß (35) .
Other growth factors, besides TGF-ß, also lead to the phenomenon of EMT, although the findings have not been as consistent. Fibroblast growth factor (FGF) caused mouse podocytes to undergo EMT in one study (36) , while epidermal growth factor (EGF) co-incubated with TGF-ß led to the same results in tubular cells (37) . In our experience EGF and FGF both were able to induce EMT in HK-2 cells, but only at high doses (100 ng/mL) (unpublished data). A member of the TGF-ß superfamily of receptors, activin A, has been shown to promote cell proliferation, enhance expression of type I collagen mRNA, and induce production of α-SMA in a rat kidney fibroblast cell line (33) . Similarly a member of the IL-6 family of cytokines, oncostatin M, induced EMT in HK-2 cells (13) . Even though the renin-angiotensin-aldosterone axis is intimately involved in kidney fibrosis, angiotensin II by itself does not induce EMT (30) . However angiotensin II when combined with TGF-ß markedly promoted EMT (30) . Type I collagen also has been shown to promote EMT (30) .
As more and more data accumulates implicating TGF-ß as causing EMT, it becomes more necessary to find inhibitors of TGF-ß. Although it may not be practical in humans, TGF-ß antibody administration is the simplest method to inhibit TGF-ß. In mice TGF-ß antibody administration at the time of induction of mesangial proliferative glomerulonephritis prevented production of extracellular matrix and dramatically attenuated histological manifestation of the disease (17) . Decorin, a well known inhibitor of TGF-ß, has also had promising results in preventing fibrosis from occurring (35) . Finally menin (nuclear protein encoded by the MEN 1 gene) has been shown to inhibit smad3 (TGF-ß signalling molecule) and prevent TGF-ß action (38) .
One can also prevent fibrogensis by inhibiting EMT without going through TGF-ß. A logical approach would be to inhibit any of the steps of the transformation process. Success has been obtained with agents that disrupt the actin cytoskeleton. Cytochalasin D prevented phenotypic alteration in proximal tubular cells following addition of TGF-ß by disrupting the actin cytoskeleton. Similarly nocodazole (a microtubule disrupting agent) has been studied in inhibiting EMT with some success (39) . Two promising growth factors -hepatocyte growth factor (HGF) and bone morphogenetic peptide (BMP) -have been shown to not only prevent EMT but also to reverse it (22, 40) . While type I collagen promotes EMT, type IV collagen probably suppresses it (30) . Finally ablation of tissue plasminogen activator selectively blocked tubular EMT from taking place (30) .
Contribution of EMT to organ fibrosis
Liu stated that myofibroblast activation in obstructed kidneys occurs at first through local activation of resident fibroblasts and at later stages through EMT (30) . The best available data comes from Nielson's experiments on transgenic reporter mice (28) . It was found that in the normal kidney tissue, bone marrow fibroblasts contribute to no more than 12% of the expected resident fibroblasts. During fibrogenesis, the percentage increases to 15% of the FSP1+ fibroblasts, while EMT accounts for 35-42% of FSP1+ interstitial cells.
The signaling pathway of TGF-ß
Since the discovery of the role of TGF-ß in causing EMT, there has been great effort to piece together the signaling mechanism. Even though great progress has been made, we are far from detailing the exact mechanism of how TGF-ß leads to EMT. The main difficulty is the fact that after 4 hours of TGF-ß treatment, about 4000 genes are activated (41) . Furthermore the communication between all these proteins is even more complicated. In order to better clarify the mechanism of action, each signaling pathway has to be studied individually.
Binding of TGF-ß to its receptor is the first event in this complicated signaling pathway. There are 2 distinct TGF-ß receptors, type I and type II (3). TGF-ß is only able to bind to the type II receptor. After TGF-ß binds to the type II receptor, type I receptor is recruited and activated. Signaling is further propagated through the type I receptor. There are at least six different subtypes of the type I receptor (3).
At least for now, the main signaling pathway for TGF-ß is thought to be the smad pathway. Scientists studying Drosophila found a gene that mediates embryologic patterning regulated by a bone morphogenetic protein homologue called decapentaplegic (41) . At the same time investigators looking at the developmental genetics of Caenorhabditis Elegans identified a series of proteins that, when mutated, produced an identical small phenotype in the worms, calling them the Sma proteins (41) . The term smad was formed when they realized the two proteins (Mad and Sma) are the same (41) . After TGF-ß binds to its receptor, type I receptor phosphorylates both smad 2 and smad 3 (3, 5, 42) . The two smads then combine and activate smad 4, causing the entire complex to translocate into the nucleus, where transcription of specific proteins is regulated (3, 5, 42) . Induction of smad 2 and smad 3 occurs after 5 minutes of TGF-ß activation, with maximal activation occurring at 15 minutes (data obtained on mesangial cells) (42) . Overall there are 3 types of smads, receptor or R-smads (bind to the TGF family receptors), Co-smads (combine with R-smads and translocate to the nucleus), and inhibitory of I-smads (prevent binding of Rsmads to the type I receptors) (39) . R-smads include smads 2 and 3 for TGF-ß and smads 1,5, and 8 for BMPs, Co-smad is smad 4 and I-smads are smad 6 and 7 (39) . Out of all the smads, smad 3 seems the most crucial in EMT. With both TGF-ß treatment and during EMT, it has been shown that smad 3 mRNA and protein expression is downregulated while smad 2 and 4 were less affected (42, 43) . Restoring smad 3 does not reverse EMT, but restores the cell cycle arrest induced by TGF-ß (43). Studies in mice have shown that absence of smad 3 protects against streptozotosin-induced diabetic nephropathy, and tubulointerstitial fibrosis induced by unilateral ureteral obstruction (5, 44, 45) . Also in one study, activation of smad 7 (inhibitory smad) decreased effects of TGF-ß (21) . However the role of smads in EMT has been questioned by one investigator who found that smads were not involved in EMT but were only involved in collagen production (12) .
Mitogen Activated Protein (MAP) kinases are a major group of signaling molecules involved in signal transduction of many different growth factors. There are three major pathways in the MAP kinase signal transduction. With TGF-ß, the ERK and the JNK pathways of the MAP kinase system are activated (19) . Although evidence that the MAP kinase pathway is involved in EMT is lacking, there may be cross talk between the ERK and the smad pathways in TGF-ß stimulated cells (19) . Also the ERK pathway may be involved in TGF-ß mediated collagen I gene transcription (19) .
Other than the smads and the MAP kinases, there are 3 proteins that deserve special mention in the TGF-ß signaling. 
Is EMT reversible?
Reversing EMT could provide a new tool for treating chronic kidney diseases. In 2002, Tian et al found that withdrawing TGF-ß from HK-2 cells at 2 days after EMT leads to the reversal of EMT (11) . In our experience we were able to reverse EMT by withdrawing TGF-ß and supplementation with media containing 20% Fetal Bovine Serum (FBS) at 4 days but not at 8 days (15) . Supplementation with media containing 2.5% FBS did not result in significant reversal of EMT (15) . In embryogenesis, supplementation with HGF causes mesenchymal to epithelial reverse transformation (48) . Reversal of EMT has also been demonstrated by treatment with HGF (22) . A member of the TGF-ß superfamily, BMP-7 has been shown to reverse TGF-ß induced EMT by reintroduction of E-cadherin (40) . Preliminary data on reversal of EMT is promising, but at least for now the reversal is limited to merely a few days after the transformation has occurred. More definitive experiments on the ability of these factors to reverse EMT in animals and humans are needed in the future.
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